Los Angeles Capital Management LLC Invests $77,000 in Assertio Holdings, Inc. (NASDAQ:ASRT)

Los Angeles Capital Management LLC purchased a new position in shares of Assertio Holdings, Inc. (NASDAQ:ASRT) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm purchased 61,992 shares of the company’s stock, valued at approximately $77,000. Los Angeles Capital Management LLC owned about 0.07% of Assertio at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of the stock. SummerHaven Investment Management LLC increased its position in shares of Assertio by 10.9% in the second quarter. SummerHaven Investment Management LLC now owns 161,171 shares of the company’s stock valued at $200,000 after acquiring an additional 15,779 shares during the period. Empowered Funds LLC raised its position in Assertio by 8.2% during the 1st quarter. Empowered Funds LLC now owns 380,417 shares of the company’s stock valued at $365,000 after purchasing an additional 28,809 shares during the last quarter. TSP Capital Management Group LLC raised its position in Assertio by 18.5% during the 1st quarter. TSP Capital Management Group LLC now owns 214,500 shares of the company’s stock valued at $206,000 after purchasing an additional 33,550 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Assertio by 0.8% in the 1st quarter. Vanguard Group Inc. now owns 4,919,614 shares of the company’s stock worth $4,719,000 after buying an additional 41,071 shares during the period. Finally, Denali Advisors LLC grew its position in shares of Assertio by 286.9% in the 1st quarter. Denali Advisors LLC now owns 165,200 shares of the company’s stock worth $158,000 after buying an additional 122,500 shares during the last quarter. 48.96% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ASRT has been the subject of a number of research analyst reports. Maxim Group began coverage on Assertio in a research note on Friday, July 26th. They issued a “buy” rating and a $3.00 price target for the company. HC Wainwright initiated coverage on shares of Assertio in a research report on Wednesday, July 3rd. They set a “buy” rating and a $4.00 price target on the stock. Finally, Alliance Global Partners initiated coverage on shares of Assertio in a research note on Tuesday, May 28th. They issued a “buy” rating and a $2.75 price target for the company. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, Assertio has an average rating of “Moderate Buy” and a consensus target price of $3.44.

Assertio Trading Up 1.6 %

Assertio stock opened at $1.24 on Tuesday. Assertio Holdings, Inc. has a one year low of $0.73 and a one year high of $2.76. The business’s fifty day moving average is $1.33 and its 200 day moving average is $1.13. The stock has a market capitalization of $117.96 million, a PE ratio of -0.31 and a beta of 0.79. The company has a debt-to-equity ratio of 0.29, a current ratio of 1.93 and a quick ratio of 1.51.

Assertio (NASDAQ:ASRT) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.02). Assertio had a negative net margin of 261.08% and a positive return on equity of 4.88%. The company had revenue of $31.13 million for the quarter, compared to analysts’ expectations of $30.37 million. During the same period in the previous year, the business earned $0.13 EPS. On average, sell-side analysts predict that Assertio Holdings, Inc. will post -0.17 EPS for the current year.

Assertio Profile

Assertio Holdings, Inc, a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis.